Absci (ABSI) Stock Price, News & Analysis

Company Overview

Absci Corporation is a biotechnology company that uses artificial intelligence and integrated laboratory technologies to discover and develop new biologic medicines. Its platform combines generative artificial intelligence with biological data and wet-lab experimentation to design therapeutic proteins and antibodies, with the goal of improving the speed and efficiency of drug development.

The company’s capabilities include target discovery, protein design, antibody generation, and experimental validation. Absci has focused on creating novel biologics, including de novo antibody candidates designed with the help of artificial intelligence, and works with pharmaceutical and biotechnology companies through collaborations and partnerships.

Founded in 2011, Absci is headquartered in Vancouver, Washington. The company serves the global biopharmaceutical industry and is led by founder and Chief Executive Officer Sean McClain.

Key Stats

• Today's Range: $8.29 to $9.83
• 50-Day Range: $6.90 to $11.47
• 52-Week Range: $2.24 to $12.06
• Volume: 8.65 million shs
• Average Volume: 4.31 million shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.71
• Consensus Rating: Moderate Buy

Absci Stock Analysis - MarketRank™

Absci scored higher than 64% of companies evaluated by MarketBeat, and ranked 321st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Absci has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Absci has a consensus price target of $13.71, representing about 46.1% upside from its current price of $9.39.

Amount of Analyst Coverage

Absci has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Absci are expected to grow in the coming year, from ($0.74) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Absci is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Absci is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Absci has a P/B Ratio of 7.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.96% of the float of Absci has been sold short.

Short Interest Ratio / Days to Cover

Absci has a short interest ratio ("days to cover") of 12.53, which indicates bearish sentiment.

Change versus previous month

Short interest in Absci has recently decreased by 1.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Absci does not currently pay a dividend.

Dividend Growth

Absci does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.74

News Sentiment

Absci has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Absci this week, compared to 4 articles on an average week.

Search Interest

18 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

12 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Absci insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.52% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABSI
• CIK: 1672688
• Web: www.absci.com
• Phone: 360-949-1041
• Fax: N/A
• Employees: 140
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Absci: $13.71
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: +47.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$115.18 million
• Net Margins: -7,756.38%
• Pretax Margin: -7,756.37%
• Return on Equity: -61.71%
• Return on Assets: -54.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.63
• Quick Ratio: 10.63

Sales & Book Value

• Annual Sales: $2.80 million
• Price / Sales: 568.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: 7.36

Miscellaneous

• Outstanding Shares: 171,610,000
• Free Float: 153,560,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 2.42